All In Biotech

Drug Trial Radar · NCT07567846

A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer

A Phase I/II Dose-escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Patients With Advanced or Metastatic Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

260

Planned (sponsor's estimate)

Start

Apr 29, 2026

Primary completion

Nov 30, 2027

Study completion Dec 30, 2027

Sponsor

Lead sponsor
Genentech, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
May 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-1261 in participants with advanced or metastatic prostate cancer. It's also to identify a recommended dose(s) and regimen for GDC-1261 for subsequent studies.

Conditions

  • Advanced Prostate Cancer
  • Metastatic Prostate Cancer

Interventions

  • GDC-1261Drug

    Participants will receive GDC-1261 as per the schedule described in the protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Adverse Events (AEs)Time frame: Up to approximately 24 months
  2. Incidence and Nature of DLTs Dose-limiting Toxicities (DLTs)Time frame: From Day 1-28 of Cycle 1 (1 Cycle = 28 days)

Locations

6 sites in 3 countries. Site status is shown where the registry gives one.

  • Honor Health Research Institute

    Scottsdale, Arizona · Recruiting

  • Yale Cancer Center

    New Haven, Connecticut · Recruiting

  • Sarah Cannon Research Institute

    Nashville, Tennessee · Recruiting

  • St Vincent's Hospital Sydney

    Darlinghurst, New South Wales, Australia · Recruiting

  • Austin Hospital

    Heidelberg, Victoria, Australia · Recruiting

  • The Royal Marsden in Sutton, Surrey - Downs Rd

    Sutton, Surrey, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.